MASTER SERVICES AGREEMENT between SAMSUNG BIOLOGICS CO., LTD. and CHECKPOINT THERAPEUTICS, INC.Master Services Agreement • November 6th, 2020 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS MASTER SERVICES AGREEMENT (this “MSA”) is made and entered into as of the date of last signature below (the “Effective Date”) by and between Checkpoint Therapeutics, Inc., a Delaware corporation having its principal place of business at 2 Gansevoort St., 9th Floor, New York, NY 10014 (“Client”), and Samsung BioLogics Co., Ltd., a company with offices at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
FIFTH AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 6th, 2020 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
Fifth Amendment (this “Amendment”) dated as of September 24, 2020 to the Executive Employment Agreement (the “Agreement”) dated October 13, 2015, as amended, by and between Checkpoint Therapeutics, Inc. (the “Company” or “Checkpoint”) and James F. Oliviero III (“Oliviero”). All capitalized terms not otherwise defined herein shall have the meanings given to them in the Agreement.
